Key result
Cardiac biomarker ratios, particularly BNP/Troponin I and NT-proBNP/Troponin I, consistently demonstrated superior diagnostic accuracy in distinguishing Takotsubo cardiomyopathy from acute coronary syndrome compared to individual markers.
Why the study?
Takotsubo cardiomyopathy clinically mimics acute coronary syndrome, leading to misdiagnosis and inappropriate treatment, while disease-specific diagnostic markers remain lacking.
Do cardiac biomarkers and their ratios accurately differentiate Takotsubo cardiomyopathy from acute coronary syndrome?
Comparison
Established and emerging cardiac biomarkers evaluated for distinguishing TTS from ACS
Design
Systematic review
Authors
Loading...
BNP/Troponin I ratio may aid TTS differentiation from ACS when single markers are inconclusive; extends diagnostic evidence for ratio-based strategies.
Systematic Review (n=3,602)
Do cardiac biomarkers and their ratios accurately differentiate Takotsubo cardiomyopathy from acute coronary syndrome?
While individual biomarkers like troponin lack specificity, biomarker ratios such as BNP/Troponin I offer superior diagnostic accuracy in distinguishing Takotsubo cardiomyopathy from acute coronary syndrome.
Shreya Garikipaty (2025) conducted a systematic review in Takotsubo cardiomyopathy (n=3,602). Cardiac biomarkers (e.g., BNP, NT-proBNP, Troponin, biomarker ratios) vs. Acute coronary syndrome (ACS) was evaluated on Diagnostic accuracy in differentiating Takotsubo cardiomyopathy from acute coronary syndrome. Cardiac biomarker ratios, particularly BNP/Troponin I and NT-proBNP/Troponin I, consistently demonstrated superior diagnostic accuracy in distinguishing Takotsubo cardiomyopathy from acute coronary syndrome compared to individual markers.